SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Globe Newswire•14/10/2026•08:30 ET
0
Key Highlights
- ➤SAB BIO management to participate in Chardan 10th Annual Healthcare Conference October 20, 2026
- ➤Samuel J. Reich scheduled to present a fireside chat from 11:15–11:30 a.m. ET
- ➤SAB-142 undergoing registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 autoimmune T1D patients
- ➤SAB BIO offers one-on-one investor meetings during the healthcare conference
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference:
Date: October 20, 2026 Time: 11:15 - 11:30 a.m. ET Format: Fireside Chat Presenter: Samuel J. Reich, Chief Executive Officer Location: New York, NY Webcast: Register here
Get started
Create a free account to read the full story.